Search

Access to Healthcare Strategy Sustainable Access Models

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.

Investigational treatment slowed lung function decline in IPF

Telemedicine – the standalone study that became the new normal

Dr Vijay Prabhakar tells us how a remote healing project made him a pandemic pioneer.Read it now!

Stroke Prevention in AF

Social Support

People living with cancer share their perspectives on the importance of social support.

Acute Ischaemic Stroke

European Commission decision for Pradaxa® in children with VTE

Pradaxa® (dabigatran etexilate) receives EU marketing authorization for the treatment and prevention of VTE in children from birth to less than 18 years of age

SPEVIGO CHMP positive opinion new indications

CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®

Disentangling fibrosis

Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.

Facts About IPF

IPF is a debilitating and fatal lung disease.

Breakthrough-Therapy-Designation-Progressive-Fibrosing-ILD

FDA Grants nintedanib Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype

Improving Access to Healthcare

According to the UN Sustainable Development Goals, almost half of the global population is not covered by essential health services.

“My ultimate goal is to cure cancer”

Norbert Kraut, our Global Head of Cancer Research, shares how we are advancing science to bring new treatment options for people living with cancer.

trust-through-transparency

Transparency is an essential cornerstone of trust in the healthcare industry

In-Reach Africa initiatives successfully completed

We are proud to report the successful completion of Kuza Afya and Tiba Yako, two of our In-Reach Africa initiatives.

Positive results Diabetic Macular Ischemia treatment

HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment

European_Commission_approves_nintedanibSSc-ILD

Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease

Advancing health equity for rural doctors in Mexico

Our virtual sales team helps doctors stay informed through digital education about the latest treatments, regardless of their location

SIRPα Cancer Immunology Research

Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.

New study paves the way for liver cirrhosis treatments

The ADVANCE study will be the most detailed observational study of its kind providing a detailed analysis of liver health.

European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis

Facts About Asthma

Understand more about what asthma is, how asthma is diagnosed and what you can do to reduce symptoms in your day to day life.

Investing in our people University of Medicine Excellence

Almost one thousand of our employees have graduated from a program developed together with Harvard Medical School’s Executive Education.

Spotlight on GPP

Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.

The GPP Forum Report

The generalized pustular psoriasis (GPP) Forum Report summarizes and highlights the important moments form the multistakeholder GPP Forum

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers